Could a lower chemo dose make transplants safer for older patients?

NCT ID NCT04959175

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a lower dose of the drug cyclophosphamide, given after a bone marrow transplant, can reduce side effects while still preventing the donor's immune cells from attacking the recipient's body (graft-versus-host disease). The trial includes adults aged 18-85 with blood cancers that haven't responded well to standard treatments. Participants receive a stem cell transplant along with chemotherapy and radiation, followed by the lower-dose cyclophosphamide, and are monitored for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclophosphamide
What this could lead to: If successful, this could make bone marrow transplants safer for older or frailer patients by reducing severe side effects from the standard chemotherapy dose.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 320 participants, so the lower dose may not prevent graft-versus-host disease as effectively, or side effects could still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC NEOPLASMS

Contacts and locations

Locations

Hospital of the University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.